IMTX

Stock ticker: NASDAQ

PRICE

CHANGE

CAPITALIZATION

Immatics (IMTX) Earnings Date & Reports

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients... Show more

Get AI intraday signals

A.I. Advisor

published Earnings

IMTX is expected to report earnings to fall 13.55% to -28 cents per share on August 12

Q2'25

Est.

$-0.29

Q1'25

Missed

by $0.07

Q4'24

Beat

by $0.74

Q3'24

Beat

by $0.14

Q2'24

Beat

by $0.11

The last earnings report on May 13 showed earnings per share of -33 cents, missing the estimate of -25 cents. With 794.35K shares outstanding, the current market capitalization sits at 554.27M.

View a ticker or compare two or three

Compare

IMTX

Setup

Buy or SellView

Daily Signalchanged days ago

Gain/Loss if bought

View Trends For IMTX
(Try 14 days for Free)

Ad is loading...

A.I.Advisor

published price charts

View to see Real Time Patterns for IMTX (Try 14 days for Free)

A.I. Advisor

published General Information

General Information

a clinical stage biopharmaceutical company, which engages in the research and development of T cell receptor-based immunotherapies for the treatment of cancer

Industry Biotechnology

Profile

Fundamentals

Details

Industry

N/A

Address

Paul-Ehrlich-Strasse 15

Phone

+49 707153970

Employees

343

Web

https://www.immatics.com